新型降压药物演示文稿.pptVIP

The rise in PRA that is observed with ACEIs and ARBs can be neutralized by the addition of Rasilez?. In a study designed to investigate the effect of Rasilez? combined with an ARB on PRA and angiotensin levels, 12 healthy male volunteers (aged 18–35 years) received single doses of Rasilez? 300?mg, valsartan 160?mg, Rasilez?/valsartan 150/80?mg combination therapy, and placebo, each separated by 14-day washout periods. The ARB-induced increase in PRA was neutralized when both Rasilez? and valsartan were administered together. Within 1 hour of administration, PRA was reduced with Rasilez? compared with placebo and maintained at normal levels for 48 hours. Furthermore, Rasilez? has been shown to neutralize drug-induced PRA rises when combined with ACEIs and diuretics in phase III clinical studies. Reference Azizi M, Ménard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15:3126–3133. Levels of Ang I and Ang II were increased by the administration of valsartan alone, but when valsartan was combined with Rasilez?, there was no increase in either metabolite above the levels observed in patients taking placebo. Reference Azizi M, Ménard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15:3126–3133. In Study 2201, Rasilez? provided significantly greater BP reductions compared with placebo (p0.005). Rasilez? 300 mg provided reductions of 15.8 mmHg and 11.8 mmHg for mean sitting SBP and DBP, respectively. Rasilez? 150 mg od provided similar reductions in mean sitting DBP and SBP to irbesartan 150 mg od. The higher dosages of Rasilez? (300 and 600?mg od) both lowered mean sitting DBP signific